It's good to be Valeant Pharmaceuticals (NYSE: VRX).

Amid the company's acquisition of Bausch + ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE